

SCOLR Pharma, Inc.  
Form 8-K  
March 16, 2010

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

**Form 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of report (date of earliest event reported):**

**March 11, 2010**

**SCOLR Pharma, Inc.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**  
  
**of incorporation)**

**001-31982**  
**(Commission File No.)**

**19204 North Creek Parkway, Suite 100**

**91-1689591**  
**(I.R.S. Employer**  
  
**Identification No.)**

Edgar Filing: SCOLR Pharma, Inc. - Form 8-K

**Bothell, WA 98011**

**(Address of principal executive offices)**

**(425) 368-1050**

**(Registrant's telephone number, including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events.**

On March 11, 2010, SCOLR Pharma, Inc., a Delaware corporation (the Company) purchased from Advanced Healthcare Distributors, LLC, a New Hampshire limited liability company (ADC), all of ADC's right, title, and interest in and to the NUPRIN® trademark worldwide, excluding Canada. The Company paid \$180,000 in cash for these rights to the NUPRIN® trademark. On March 16, 2010 the Company issued a press release regarding this transaction, a copy of which is attached as exhibit 99.1.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

<b>Exhibit No.</b>	<b>Description</b>
99.1	SCOLR Pharma, Inc. press release, dated March 16, 2010.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**SCOLR PHARMA, INC.**

Dated: March 16, 2010

By: /s/ Richard M. Levy  
Chief Financial Officer